Inactive Instrument

SourcingLink.net, Inc. Stock OTC Bulletin Board

US8361714053

Valuation: SourcingLink.net, Inc.

Market Cap	2.71M 2.35M 2.19M 2.01M 3.8M 258M 3.86M 25.81M 10.13M 129M 10.16M 9.94M 431M	P/E 2003 *	-	P/E 2004	-
Enterprise Value	2.71M 2.35M 2.19M 2.01M 3.8M 258M 3.86M 25.81M 10.13M 129M 10.16M 9.94M 431M	EV / Sales 2003	-	EV / Sales 2004	-
Free-Float	100%	Yield 2003 *	-	Yield 2004	-

* Estimated data More valuation ratios

Latest news : SourcingLink.net, Inc.

24-10-02	Krystal Biotech, Inc. : Will it go even higher?
21-03-30	NanoSmart Pharmaceuticals, Inc. announced that it has received funding from Oncology Pharma Inc.	CI
21-03-10	Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy	CI
21-03-04	Oncology Pharma Inc. Moves to Fund Lead Drug Formulation & IND-Enabling Studies	CI
21-02-26	Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent	CI
21-02-22	Oncology Pharma Extends Licensing Agreement with Nanosmart Pharmaceuticals, Inc. for Veterinary Oncology	CI
21-02-16	Oncology Pharma Inc. Announces Henry Smith as New Chairman to Its Scientific Advisory Board	CI
21-02-09	Oncology Pharma Renews Licensing Agreement with Ribera Solutions LLC for Its Connect2med Clinical Trials Platform	CI
21-01-28	Oncology Pharma Announces the Appointment of James Smith as New Chief Financial Officer	CI
20-12-10	Oncology Pharma Inc. cancelled the acquisition of acquire 50% stake in Diagnomics, Inc.	CI
20-04-06	Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating Covid-19	CI
19-12-19	Oncology Pharma Inc. announced that it expects to receive $38.4 million in funding from SCP Partners	CI
19-12-10	Oncology Pharma Inc. signed a Letter of Intent to acquire 50% stake in Diagnomics, Inc.	CI

More news

Press Releases: SourcingLink.net, Inc.

22-07-12	Oncology Pharma : Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System	PU
22-06-29	Oncology Pharma : Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System	PU
22-06-06	Oncology Pharma : Financial Statements (Unaudited) for the year ended March 31, 2022	PU
22-02-14	Oncology Pharma : Financial Statements for the period ended December 31, 2021	PU
22-02-14	Oncology Pharma : Disclosure Statement for the period ended December 31, 2021	PU

More press releases

News in other languages: SourcingLink.net, Inc.

24-10-07

Krystal Biotech, Inc. : ¿Subirá aún más?

More news

Managers and Directors: SourcingLink.net, Inc.

Manager	Title	Age	Since
George Malesek CEO	Chief Executive Officer	-	-

More insiders

Oncology Pharma, Inc. is an oncology company. The Company is focused on licensing, developing, manufacturing and commercializing therapeutics. The Companyâ€™s research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The Company offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals). The Companyâ€™s NanoSmart platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. Its anti-cancer drugs in combination with medications, for treating a variety of cancers, such as breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia is doxorubicin. Its portfolio also includes Connect2Med, Sybleu, Inc. and Regen.

Employees

Sector

Pharmaceuticals

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SOURCINGLINK.NET, INC.	-.--%	+9.50%	-	-	2.71M
ELI LILLY AND COMPANY	-0.53%	-3.95%	+50.70%	+153.56%	1,024B
JOHNSON & JOHNSON	+0.21%	-2.68%	+53.20%	+51.79%	618B
ABBVIE INC.	-2.51%	-3.25%	+28.54%	+68.94%	443B
ROCHE HOLDING AG	+0.06%	-0.42%	+37.53%	+30.67%	349B
NOVARTIS AG	-0.14%	-0.24%	+34.41%	+39.01%	297B
ASTRAZENECA PLC	-0.69%	-0.30%	+13.76%	+12.83%	264B
NOVO NORDISK A/S	-7.37%	-4.40%	-0.74%	-44.28%	209B
AMGEN INC.	-0.64%	+2.43%	+29.74%	+65.93%	208B
GILEAD SCIENCES, INC.	-0.82%	+0.70%	+15.05%	+72.05%	162B
Average	-1.24%	-1.20%	+29.13%	+50.05%	397.08B
Weighted average by Cap.	-0.99%	-1.93%	+37.18%	+73.22%

	2003	2004
Net sales	3.28M 2.85M 2.65M 2.44M 4.6M 313M 4.67M 31.28M 12.28M 156M 12.32M 12.05M 523M	1.18M 1.03M 956K 877K 1.66M 113M 1.68M 11.26M 4.42M 56.13M 4.44M 4.34M 188M
Net income	-1.52M -1.32M -1.23M -1.13M -2.13M -145M -2.17M -14.5M -5.69M -72.24M -5.71M -5.58M -242M	-1.56M -1.36M -1.27M -1.16M -2.2M -149M -2.23M -14.93M -5.86M -74.38M -5.88M -5.75M -249M
Net Debt	-1.35M -1.17M -1.09M -1M -1.89M -128M -1.92M -12.84M -5.04M -63.97M -5.06M -4.94M -214M	17K 14.78K 13.76K 12.63K 23.85K 1.62M 24.22K 162K 63.63K 808K 63.85K 62.44K 2.71M

SourcingLink.net, Inc. Stock OTC Bulletin Board

Stocks